Metastatic breast lobular carcinoma to tamoxifen-associated endometrial polyp: case report and literature review.
Tamoxifen is a widely used adjuvant treatment of breast carcinoma with partial estrogenic agonist effect. This activity may result in a spectrum of proliferative endometrial abnormalities including uterine polyps. We report a 53-year-old woman receiving tamoxifen for previously excised breast lobular carcinoma who presented with vaginal bleeding. Histologic examination of the endometrium revealed typical morphology of tamoxifen-associated polyp with foci of metastatic lobular carcinoma. Metastatic breast carcinoma to tamoxifen-associated polyp has rarely been described in the literature. Pathologists and gynecologists should be aware of this possibility in women who have a history of breast carcinoma and who are receiving tamoxifen. Careful histologic evaluation of the endometrium is crucial.
Al-Brahim
Nabeel
N
Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario L8N 3Z5, Canada.
Elavathil
Leelamma J
LJ
D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects*; D014408:Biomarkers, Tumor / Q000032:analysis; D001943:Breast Neoplasms / Q000737:chemistry / Q000473:pathology* / Q000628:therapy; D018275:Carcinoma, Lobular / Q000737:chemistry / Q000556:secondary* / Q000628:therapy; D003131:Combined Modality Therapy; D016889:Endometrial Neoplasms / Q000139:chemically induced* / Q000378:metabolism / Q000556:secondary / Q000601:surgery; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011127:Polyps / Q000139:chemically induced* / Q000737:chemistry / Q000473:pathology / Q000601:surgery; D013629:Tamoxifen / Q000009:adverse effects*
D018931:Antineoplastic Agents, Hormonal; D014408:Biomarkers, Tumor; D013629:Tamoxifen